Scope and claims for US Patent 11,103,483 (bendamustine-ready-to-use liquid with PEG and antioxidant-stabilized impurity limits)
US 11,103,483 is a formulation and therapeutic-use patent focused on a ready-to-use liquid bendamustine composition with: (i) bendamustine concentration 10–100 mg/mL, (ii) polyethylene glycol (PEG), (iii) an antioxidant stabilizing amount selected from a defined list (including lipoic acid, thioglycerol, gallate, methionine/cysteine, metabisulfites, sodium formaldehyde sulfoxylate, phenolic antioxidants, and dihydrolipoic acid), and (iv) stability control via an HPLC impurity threshold: <5% peak area response of total impurities from bendamustine degradation after ≥15 months at 5°C to 25°C, measured by HPLC at 223 nm. Dependent claims tighten concentration ranges and antioxidant selections and also recite cancer-treatment methods using the claimed composition.
Key business conclusion: the patent’s enforceable core is not “bendamustine + antioxidant,” but the combination of a PEG-containing ready-to-use liquid plus a specific degradation-impurity acceptance criterion under accelerated/real-time stability conditions and a defined concentration band. Designing around typically requires breaking at least one of the claim anchors: (a) remove PEG or change PEG function/level outside literal coverage, (b) avoid the enumerated antioxidant set or avoid “stabilizing amount” as construed, (c) change the impurity profile to exceed the <5% total-degradation-impurity requirement (or to change the assay/conditions so literal infringement fails, while still meeting the product quality reality), or (d) shift the bendamustine concentration outside 10–100 mg/mL (or specifically avoid 20–60 mg/mL and 25 mg/mL if those dependents matter).
What is US Patent 11,103,483 and what does it claim for bendamustine liquid formulations?
Direct claim target (independent claim 1): a ready-to-use liquid bendamustine formulation comprising:
- Bendamustine (or pharmaceutically acceptable salt), 10–100 mg/mL
- Polyethylene glycol (PEG)
- Stabilizing amount of an antioxidant
- Stability requirement: < about 5% peak area response of total impurities from bendamustine degradation by HPLC at 223 nm after at least 15 months at 5°C–25°C
“Ready-to-use liquid” is a claim limiter. It is typically used to exclude reconstitution-required formats and can also exclude concentrates if construed as not ready-to-administer without further dilution/handling.
What does “total impurities resulting from degradation of bendamustine” mean for scope?
Claim 1 ties infringement to the analytical outcome, not just ingredient lists. It requires that the formulation’s HPLC impurity signal representing degradation impurities of bendamustine stays below ~5% total peak area response after ≥15 months at the specified temperature window.
Impact on claim scope:
- A competitor cannot “rename” impurities. The claim’s wording frames the impurity set as those “resulting from degradation of bendamustine,” which in practice will be mapped to impurity peaks defined/validated in the patent’s disclosure and prosecution history.
- The HPLC detection wavelength is fixed at 223 nm, which can matter if competitors use different methods or method variants that materially change peak assignment or response.
What does the temperature/stability condition window cover?
Claim 1 requires the impurity limit after at least 15 months at about 5°C to about 25°C. Dependent claims later lock each endpoint:
- Claim 3: impurity limit after ≥15 months at about 5°C
- Claim 4: impurity limit after ≥15 months at about 25°C
This creates two “paths” to infringement even if a formulation performs differently at refrigerated vs room temperature.
Why PEG is a central scope limiter
PEG appears as a required component in claim 1. If a competitor uses a different polymer/excipient system (e.g., polysorbates, PVP, cyclodextrins, or other viscosity/stabilizers) and does not include PEG, literal infringement is materially weakened.
What is the antioxidant claim architecture?
Claim 1 uses “an antioxidant” in a stabilizing amount, while claim 2 enumerates acceptable antioxidant species. Claim 11 similarly enumerates antioxidants for the method claims. Dependent enumerations can narrow scope if claim construction treats them as limiting for those dependents, while claim 1 may remain broader if “antioxidant” is interpreted functionally.
Which antioxidants and salts are explicitly covered by US 11,103,483?
Dependent claim 2: antioxidant list (composition)
Claim 2 specifies antioxidants from a defined set, including:
- lipoic acid
- thioglycerol
- propyl gallate
- methionine
- cysteine
- metabisulfite (as referenced in the antioxidant list)
- sodium formaldehyde sulfoxylate
- phenol-containing aromatic compound
- phenol-containing aliphatic compound
- dihydrolipoic acid
- mixtures thereof
Scope effect: For claim 2, infringement is tied to whether the antioxidant in the product falls within these listed categories and whether it is present at a “stabilizing amount” consistent with the patent’s disclosure.
Dependent claim 7: bendamustine hydrochloride
Claim 7 narrows to bendamustine hydrochloride. This matters if competitor products use a different salt form (or a salt-free base with different counterion chemistry).
Antioxidant in method claims
Claims 11 parallels claim 2 for the method of treatment. That means method infringement can align with a specific antioxidant selection if a court treats the antioxidant list as limiting in the method dependents.
What bendamustine concentration ranges are protected in US 11,103,483?
Independent claim 1: 10 to 100 mg/mL
Bendamustine concentration in the liquid formulation must be about 10 mg/mL to about 100 mg/mL.
Dependent claim 5: 20 to 60 mg/mL
This narrower band creates heightened risk for “mid-range” strengths.
Dependent claim 6: about 25 mg/mL
If commercial packaging uses a 25 mg/mL strength, this dependent claim becomes highly relevant.
Scope conclusion: concentration selection is a primary design-around lever. Products outside 10–100 mg/mL avoid claim 1 literally; products outside 20–60 or outside 25 mg/mL avoid the dependents (though not necessarily the independent).
How does the HPLC impurity acceptance test define infringement risk?
The stability/quality threshold is a claim element
Claim 1 and dependents 3 and 4 require:
- HPLC at 223 nm
- after ≥15 months
- at 5°C and/or 25°C depending on the dependent claim
- < about 5% peak area response of total impurities attributed to degradation
Why this matters strategically
In practice, infringement often turns on whether a competitor’s product falls inside the numerical spec. This creates leverage points:
- If the competitor can show their actual stability profile yields ≥5% total degradation-impurity peak area under the same or substantially equivalent conditions, literal infringement may fail.
- If the competitor’s product is already tested to similar stability specs, the patent becomes a “test-based” risk rather than purely a formulation recipe risk.
Assay method sensitivity
Even with the same nominal wavelength (223 nm), HPLC impurity outcomes depend on:
- column, mobile phase, gradient profile, integration settings, and impurity peak identification rules
- how “total impurities” is computed from identified peaks
- what constitutes “degradation impurities” vs other impurities
Because claim language fixes at least wavelength and time/temperature and defines impurities by origin (“resulting from degradation”), competitors may still face infringement arguments if their method is deemed equivalent and their product’s degradation profile matches the patent’s definition of “total impurities” in substance.
Does the patent protect cancer-treatment methods, and what indications are specified?
Method claims (claims 8–16)
Claim 8 covers:
- a method of treating cancer in a mammal by administering an effective amount of the claimed ready-to-use liquid composition.
Indication dependents
- Claim 9: cancer is leukemia
- Claim 10: cancer is Hodgkin’s disease
Scope note: method claims typically attach to medical use rather than manufacturing or formulation alone. That said, enforcement in practice may target parties involved in marketing/administering the protected composition or may be used as leverage in litigation even if direct acts are performed by clinicians rather than manufacturers.
Method claim antioxidant and impurity limits
- Claim 11: ties antioxidant to the enumerated list
- Claim 12 and 13: ties impurity limits to 5°C and 25°C endpoints
- Claim 14 and 15: ties concentration to 20–60 mg/mL and about 25 mg/mL
- Claim 16: ties composition to bendamustine hydrochloride
How broad is the overall patent estate around US 11,103,483: formulation vs method and what “counts” as infringement?
US 11,103,483 is two-layer:
- Formulation layer (composition claims): claim 1 with dependents 2–7
- Method layer (use claims): claim 8 with dependents 9–16
Practical infringement matrix:
- A competitor that matches ingredient list and concentration but fails impurity threshold likely avoids claim 1 but may still risk dependents if their impurities stay below thresholds.
- A competitor that matches ingredient list and impurity threshold but uses no PEG (or no antioxidant from the enumerated set) could avoid dependents but may still face claim 1 if “antioxidant” is interpreted broadly.
- A competitor that matches everything except uses bendamustine salt other than hydrochloride avoids claim 7 and method dependents 16, but may still infringe claim 1/8 if “pharmaceutically acceptable salt” covers that other salt and impurity performance matches.
Design-around hierarchy (typical):
- Remove or replace PEG
- Replace antioxidant chemistry outside the enumerated list
- Shift concentration outside 10–100 mg/mL
- Achieve stability profiles where “total impurities from degradation” exceed the <5% threshold under the patent’s HPLC definition and conditions (harder if regulatory-quality constraints limit impurity excursions)
What generic or biosimilar entry risks exist for bendamustine liquid under this claim set?
Generic “ready-to-use liquid” risk pattern
If a generic manufacturer seeks to launch a ready-to-use liquid bendamustine, the risk hinges on whether their formulation:
- is within 10–100 mg/mL
- contains PEG
- uses an antioxidant and meets the <5% total degradation impurities after ≥15 months at 5°C and/or 25°C
- aligns with the chosen salt form and strength
Orange Book and Paragraph IV dynamics
This analysis cannot map infringement to a specific FDA-listed Orange Book patent entry (listed code, expiration date, or NDA/BLA linkage) from the provided information. The claims themselves create a test-based barrier for any product attempting to be “composition-equivalent” in stability and excipient system.
How to interpret the claim’s “equivalence” under practical formulation choices
Ingredient substitution
- Replacing PEG with another polymer likely breaks literal coverage of claim 1 because PEG is explicitly recited.
- Substituting one antioxidant for another can avoid dependent claims that enumerate specific antioxidants (claim 2, 11). Claim 1 may still capture other antioxidants if a court reads “an antioxidant” broadly and finds it performs a stabilizing antioxidant function.
Concentration changes
- Commercial strengths around 25 mg/mL are directly pulled into dependent claim 6 and method dependent claim 15.
- Concentrations between 20 and 60 mg/mL sit inside claim 5 and method dependent claim 14.
Stability spec replication
The impurity acceptance threshold is the hardest to “paper around.” It is a measurable formulation characteristic tied to defined HPLC conditions.
Key Takeaways
- US 11,103,483 is anchored on a ready-to-use PEG-containing bendamustine liquid with an antioxidant stabilizer and a quantitative stability/impurity limit under HPLC at 223 nm after ≥15 months at 5°C to 25°C.
- Scope is recipe-plus-performance: ingredient set and concentrations matter, but the <5% total degradation impurity requirement is a direct infringement element.
- Dependent claims narrow the business-relevant operating space: antioxidant enumerations, concentration bands (20–60 mg/mL and ~25 mg/mL), bendamustine hydrochloride, and separate impurity performance at 5°C vs 25°C.
- Method-of-use claims extend the claim utility to treating leukemia and Hodgkin’s disease using the claimed formulation, with dependents tying back to the same excipient, concentration, salt, and impurity conditions.
FAQs
1) What is the single most important limitation in claim 1 for US 11,103,483?
The requirement that the formulation has < about 5% peak area response of total impurities from bendamustine degradation by HPLC at 223 nm after ≥15 months at 5°C–25°C.
2) Does the patent cover bendamustine salts other than hydrochloride?
Claim 1 covers bendamustine or a pharmaceutically acceptable salt, while claim 7 specifically recites bendamustine hydrochloride.
3) If an antioxidant is not in claim 2’s enumerated list, can it still infringe claim 1?
Yes in principle, because claim 1 requires “an antioxidant” without limiting to the enumerated species; claim 2 narrows the antioxidant set for that dependent claim.
4) What concentrations are explicitly protected beyond the broad 10–100 mg/mL band?
20–60 mg/mL (claim 5) and about 25 mg/mL (claim 6), with corresponding method dependents.
5) Are impurity stability limits different at 5°C versus 25°C in the claim set?
Yes. Claim 3 focuses on performance at about 5°C, while claim 4 focuses on performance at about 25°C, both after ≥15 months.
References (APA)
- United States Patent 11,103,483. (n.d.). Ready-to-use liquid bendamustine-containing composition and methods of use.
